
Jerôme Fayette, MD, PhD, discusses findings from a trial of frontline petosemtamab plus pembrolizumab in patients with recurrent/metastatic HNSCC.

Your AI-Trained Oncology Knowledge Connection!


Jerôme Fayette, MD, PhD, discusses findings from a trial of frontline petosemtamab plus pembrolizumab in patients with recurrent/metastatic HNSCC.

Dr. Jérôme Fayette presents the findings of a phase 2 study (NCT03526835) assessing the overall response rate of petosemtamab in combination with pembrolizumab compared to pembrolizumab monotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Published: July 15th 2024 | Updated: